Company profile
CUMBERLAND PHARMACEUTICALS INC
NASDAQ:CPIXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VAPRISOL | approved | $0.0MQ1 2024 | 6 | approved |
| OMECLAMOX-PAK | approved | $0.0M*Q3 2025 | 39 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (47)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01887470 | phase2 | completed | 2013-07-01 | 2013-10-01 | Cumberland Pharmaceuticals | 2 Regimens of Lactulose for Colonoscopy Preparation in Adults |
| NCT02208063 | phase3 | terminated | 2014-12-01 | 2018-04-12 | Cumberland Pharmaceuticals | A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial |
| NCT01650519 | phase4 | completed | 2012-09-01 | 2012-12-01 | Cumberland Pharmaceuticals | A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery |
| NCT00712543 | phase4 | completed | 2009-06-01 | 2009-09-01 | Cumberland Pharmaceuticals | A Preference Study Comparing Kristalose® and Liquid Lactulose |
| NCT00225706 | phase3 | completed | 2005-10-01 | 2007-08-01 | Cumberland Pharmaceuticals | A Study of Caldolor in Hospitalized Febrile Pediatric Patients |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 050824 | 2011-02-08 | NDA | CUMBERLAND PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 022016 | — | NDA | CUMBERLAND PHARMS | |||||
Loading… | ||||||||